Physician profile
Sara E Malsom
NPI 1033528666
$240.20
in general payments reported to CMS, 2019-2025
9 companies · $50.85 in 2025
The $50.85 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $12.00 · 2023: $71.08 · 2024: $106 · 2025: $50.85.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $228.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $228.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $64.62 | 2023-2025 | Farxiga, Breztri |
| Takeda Pharmaceuticals U.S.A., INC. | $39.65 | 2023-2024 | Entyvio |
| Glaxosmithkline, LLC. | $30.90 | 2021-2024 | Shingrix, Bexsero, Arexvy |
| Edwards Lifesciences Corporation | $20.80 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Novo Nordisk INC | $19.80 | 2023 | Ozempic, Rybelsus |
| Lilly USA, LLC | $18.90 | 2025 | Zepbound |
| Abbvie INC. | $17.36 | 2024 | |
| Boston Scientific Corporation | $15.10 | 2024 | Watchman Access System |
| Pharmacosmos Therapeutics INC. | $13.07 | 2023 | Monoferric |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Malsom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.